USA-based biopharmaceutical firm Cytogen reported a net loss of $8.9 million, or $0.34 per diluted share, for the full year 2006, up 85.4% from the $4.8 million deficit it posted for the comparable period in 2005. It attributed the deepening losses to costs associated with its anticancer drug Soltamox (tamoxifen citrate), which was introduced in the USA last spring, as well as to expenses associated with the impending launch of the oral mucositis treatment Caphosol in the USA, which it licensed from Norwiegen group InPharma AS (Marketletter October 23, 2006).
The firm's revenues for the period, which were predominantly derived from the cancer pain medication Quadramet (samarium Sm-153 lexidronam injection) and its molecular imagining agent Prostacint (capromab pendetide), grew 7% to $4.5 million.
Cytogen also said that its selling, general and administrative expenses for the final three months of 2006 had nearly doubled, reaching $10.2 million, attributing the rise to its increased marketing activities. Conversely, the New Jersey-headquartered firm reported that it had cut is R&D expenditure 22.7% to $1.7 million. It explained that the reduction was due to higher preclinical development costs in 2005.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze